Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
Precigen (Nasdaq: PGEN) reported updated long-term durability data for PAPZIMEOS (zopapogene imadenovec-drba) in adults with recurrent respiratory papillomatosis. According to the company, 15 of 18 complete responders (83%) had ongoing complete responses for at least 36 months as of April 30, 2026, with 5 beyond 4 years; median duration not yet reached and no new safety events were observed. The FDA granted seven-year orphan drug market exclusivity.
How this was made
The 30-second read
Why it matters
Updated follow-up shows sustained complete responses without additional RRP treatments and no new safety signals, while FDA’s seven-year orphan drug market exclusivity further strengthens the competitive and revenue outlook.
Market read
For PGEN, the combination of longer follow-up durability (83% ongoing complete responses; 5 beyond 4 years) and seven-year exclusivity is a tangible fundamental positive catalyst.
What to watch
Market exclusivity timing/coverage details and any payer/access dynamics are not discussed; investors may discount if commercial uptake assumptions were already optimistic.
Background
PAPZIMEOS (zopapogene imadenovec-drba) is the first/only FDA-approved therapy for adult recurrent respiratory papillomatosis (RRP), and this release updates pivotal-study durability presented at ASCO.
Ticker impact
Precigen reports updated long-term PAPZIMEOS durability data (83% ongoing complete responses) and notes FDA granted seven-year market exclusivity.
Likely positive bias for PGEN as investors re-rate durability/market exclusivity; magnitude depends on prior expectations and broader biotech tape.
The article adds specific new follow-up datapoints (as of Apr 30, 2026) and confirms exclusivity, both directly supportive for valuation, though it’s still not a new approval/label expansion event.
Market effects
Reinforces investor appetite for durable-response immunotherapies in rare diseases; may modestly lift sentiment for similar commercial-stage biopharma.
Primarily US-focused (FDA exclusivity, ASCO presentation).
Limited direct global read-through; mostly company-specific durability and exclusivity.
Counterpoint
Durability data are supportive but still limited by small responder counts (18 complete responders), and median duration not reached may temper near-term re-rating.
Key entities
- companyPrecigen
Commercial-stage biopharmaceutical company presenting updated PAPZIMEOS long-term durability data and exclusivity status.
- drugPAPZIMEOS
Non-replicating adenoviral vector immunotherapy for adult RRP; durability data updated as of Apr 30, 2026.
- regulatorFDA
Granted seven-year orphan drug market exclusivity for PAPZIMEOS.
